An Open-Label, Dose Escalation, Phase I Study of TAK-901 in Adult Patients With Advanced Solid Tumors or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2011
At a glance
- Drugs TAK 901 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 07 Dec 2011 Actual patient number is 20 as reported by ClinicalTrials.gov.
- 07 Dec 2011 Actual end date Nov 2011 added as reported by ClinicalTrials.gov.
- 07 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.